KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Raw Materials (2016 - 2026)

Edwards Lifesciences has reported Raw Materials over the past 12 years, most recently at $196.6 million for Q4 2025.

  • For Q4 2025, Raw Materials fell 18.46% year-over-year to $196.6 million; the TTM value through Dec 2025 reached $196.6 million, down 18.46%, while the annual FY2025 figure was $196.6 million, 18.46% down from the prior year.
  • Raw Materials for Q4 2025 was $196.6 million at Edwards Lifesciences, down from $222.8 million in the prior quarter.
  • Over five years, Raw Materials peaked at $280.0 million in Q1 2024 and troughed at $196.3 million in Q4 2023.
  • A 3-year average of $236.5 million and a median of $241.1 million in 2024 define the central range for Raw Materials.
  • Biggest five-year swings in Raw Materials: increased 22.82% in 2024 and later fell 18.46% in 2025.
  • Year by year, Raw Materials stood at $196.3 million in 2023, then grew by 22.82% to $241.1 million in 2024, then fell by 18.46% to $196.6 million in 2025.
  • Business Quant data shows Raw Materials for EW at $196.6 million in Q4 2025, $222.8 million in Q3 2025, and $249.8 million in Q2 2025.